Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
Expands manufacturing push & locks in major growth deals
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Subscribe To Our Newsletter & Stay Updated
